Abraxis Bioscience dismisses patent infringement complaint filed against SPARC

WebinarsNew
Deep DiveNew
Explore Business Standard

SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Dec 09 2019 | 12:24 PM IST